Brain scans reveal how new combo drug curbs cravings in obesity
NCT ID NCT06267092
First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tested a combination medicine called CagriSema (cagrilintide and semaglutide) in 164 adults with overweight or obesity. Researchers measured changes in appetite, food intake, and brain activity using scans and questionnaires. The goal was to understand how the medicine affects hunger signals in the brain compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.